| EPD446 | Resilience of HIV-positive parents and their children within the family context in Bangladesh: A way of achieving 'self' | E-poster | Adaptation to living with HIV for individuals, families and communities |
| EPD457 | Relationship between Multi-Month ARVs Dispensing (MMD) and viral load suppression among PLHIVs accessing care in Nigeria: results from a retrospective study using 2000'2021 data | E-poster | Experiences and impacts of antiretroviral therapy |
| EPD471 | The mental health of people living with HIV: prevalence and associations of depression, anxiety and stress | E-poster | Living with HIV and co-infections and/or co-morbidities |
| EPE113 | Impact of innovative patient- centred two-way digital communication and community-based proactive cohort management on improving retention of ART clients in Zambia | E-poster | Strategies to enhance U=U communication and implementation |
| EPE221 | Key population and local government-led social contracting in Vietnam: a pathway to expanding coverage of publicly-financed HIV services | E-poster | Approaches to achieving sustainability, including sustainable financing for civil society |
| EPE417 | A pandemic triad: HIV, COVID-19 and debt in developing countries | E-poster | Impact of COVID-19 on financing for the HIV response |
| PELBA01 | Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice | Poster exhibition | Gene therapy |
| PELBA02 | First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PELBA03 | In-vitro/ ex-vivo contribution of antiretroviral drug and alcohol exposure to blood-brain barrier disruption: relevance to the pathogenesis of HIV-1 associated neurological disorder | Poster exhibition | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| PELBB01 | Final week 192 results from the ADVANCE trial: first-line TAF/FTC/DTG, TDF/FTC/DTG vs TDF/FTC/EFV | Poster exhibition | Weight gain |